Werewolf Therapeutics (HOWL) Earnings Analysis

Werewolf Therapeutics (HOWL) next reports earnings on 2026-08-13, consensus EPS -0.28 USD. Last quarter (2026-05-07) it beat with EPS -0.28 USD vs -0.32 USD est (+12.5%). It has beaten estimates in 3/4 recent quarters (75%). Trailing P/E -0.30.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does HOWL next report earnings?

Next earnings date2026-08-13
Consensus EPS estimate-0.28 USD
Revenue estimaten/a

HOWL earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-07-0.28 USD-0.32 USD+12.5%Beat
2026-03-27-0.2 USD-0.34 USD+41.2%Beat
2025-08-14-0.4 USD-0.5 USD+20%Beat
2025-03-11-0.46 USD-0.43 USD-7%Miss

Beat rate: 3/4 (75%) over reported quarters with consensus data.

HOWL valuation and analyst view

Trailing P/E-0.30
Trailing EPS-1.15779 USD
Price / book1.45
Dividend yield0.00%
Market cap0.02B
Analyst consensusBuy (8 buy / 1 hold / 0 sell)
Avg price target1 USD

Related research pages

Frequently asked questions

When is Werewolf Therapeutics (HOWL)'s next earnings date?

Werewolf Therapeutics is next scheduled to report on 2026-08-13, with a consensus EPS estimate of -0.28 USD.

Did HOWL beat earnings last quarter?

In its 2026-05-07 report, HOWL posted EPS of -0.28 USD versus a -0.32 USD estimate — a beat of 12.5%.

What is HOWL's earnings track record?

Over the last 4 reported quarters with consensus data, HOWL beat estimates 3 times (75%).

What is HOWL's current P/E ratio and EPS?

HOWL trades at a trailing P/E of -0.30 on trailing EPS of -1.1577918776038356 USD.

What do analysts rate HOWL?

Analyst consensus is "Buy" across 9 ratings (0 strong buy, 8 buy, 1 hold, 0 sell, 0 strong sell). Average 12-month price target: 1 USD.